1h Free Analyst Time
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2019Speak directly to the analyst to clarify any post sales queries you may have.
Summary
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) pipeline Target constitutes close to 16 molecules. The latest report P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Pipeline Review, H2 2019, outlays comprehensive information on the P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - P2X purinoceptor 7 is a protein encoded by the P2RX7 gene. It acts as receptor for ATP that acts as a ligand-gated ion channel. It is responsible for ATP-dependent lysis of macrophages through the formation of membrane pores permeable to large molecules. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 1, 3 and 6 respectively. Report covers products from therapy areas Central Nervous System, Immunology, Oncology, Genetic Disorders and Gastrointestinal which include indications Epilepsy, Inflammation, Neuropathic Pain (Neuralgia), Breast Cancer, Charcot-Marie-Tooth Disease Type I A, Colorectal Cancer, Depression, Lung Cancer, Multiple Sclerosis, Prostate Cancer, Alzheimer's Disease, Basal Cell Carcinoma (Basal Cell Epithelioma), Bipolar Disorder (Manic Depression), Duchenne Muscular Dystrophy, Hematological Tumor, Inflammatory Bowel Disease, Major Depressive Disorder, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Lung Cancer, Metastatic Prostate Cancer, Neuroinflammation, Pain and Solid Tumor.
Furthermore, this report also reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)
- The report reviews P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics and enlists all their major and minor projects
- The report assesses P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to P2X Purinoceptor 7 (P2Z Receptor or P2RX7) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 7 (P2Z Receptor or P2RX7)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 7 (P2Z Receptor or P2RX7) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
IntroductionReport Coverage
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Overview
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Companies Involved in Therapeutics Development
Affectis Pharmaceuticals AG
Asahi Kasei Pharma Corp
Axxam SpA
Biosceptre International Ltd
Evotec SE
Integral Molecular Inc
Johnson & Johnson
Lead Discovery Center GmbH
MindImmune Therapeutics Inc
MyoTherix Inc
Suven Life Sciences Ltd
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Drug Profiles
AFC-5128 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AKP-23494954 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIL-010t - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIL-03s - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIL-06v - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIL-07v - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EVT-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-5446 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-55308942 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize P2X7 for Immunology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MT-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small molecule to Antagonize P2X7 for Multiple Sclerosis and Epilepsy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize P2X7 Receptor for Central Nervous System - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize P2RX7 for CNS Disorders, Autoimmune Disorders and Inflammation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize P2X7 for Inflammation and Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize P2X7 for Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Dormant Products
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Discontinued Products
P2X Purinoceptor 7 (P2Z Receptor or P2RX7) - Product Development Milestones
Featured News & Press Releases
Nov 14, 2018: Update on phase I trial of vaccine BIL06v
Aug 21, 2018: Initiation of Biosceptre’s phase 1 clinical trial for first-in-class oncology vaccine BIL06v
Mar 03, 2017: Biosceptre publishes a clinical study of topical drug BIL010t as therapy for Basal cell carcinoma
Dec 18, 2014: Alzheimer’s Drug Discovery Foundation And Axxam Continue Their Successful Collaboration To Develop Novel Therapeutics For Alzheimer’s Disease
Jul 22, 2014: Biosceptre Announces Positive Phase I Results for BIL-010t to Treat Basal Cell Carcinoma
Jan 25, 2012: Affectis Receives European Patent For AFC-5128 And Other P2X7 Antagonists
Jun 29, 2009: Evotec Announces The Successful Completion Of The First Phase I Study With EVT 401
Oct 09, 2008: Evotec Announces Phase I Initiation With P2X7 Antagonist
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Affectis Pharmaceuticals AG, H2 2019
Pipeline by Asahi Kasei Pharma Corp, H2 2019
Pipeline by Axxam SpA, H2 2019
Pipeline by Biosceptre International Ltd, H2 2019
Pipeline by Evotec SE, H2 2019
Pipeline by Integral Molecular Inc, H2 2019
Pipeline by Johnson & Johnson, H2 2019
Pipeline by Lead Discovery Center GmbH, H2 2019
Pipeline by MindImmune Therapeutics Inc, H2 2019
Pipeline by MyoTherix Inc, H2 2019
Pipeline by Suven Life Sciences Ltd, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Affectis Pharmaceuticals AG
- Asahi Kasei Pharma Corp
- Axxam SpA
- Biosceptre International Ltd
- Evotec SE
- Integral Molecular Inc
- Johnson & Johnson
- Lead Discovery Center GmbH
- MindImmune Therapeutics Inc
- MyoTherix Inc
- Suven Life Sciences Ltd
